Edition:
India

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

66.46USD
8:26pm IST
Change (% chg)

$-0.07 (-0.11%)
Prev Close
$66.53
Open
$67.00
Day's High
$67.00
Day's Low
$66.43
Volume
142,945
Avg. Vol
1,770,703
52-wk High
$70.04
52-wk Low
$51.56

Latest Key Developments (Source: Significant Developments)

Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS EARNS IND MILESTONE PAYMENT UNDER IMMUNE CHECKPOINT PATHWAYS DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB AND ANNOUNCES THAT BMS HAS EXTENDED THE RESEARCH TERM OF THIS COLLABORATION FOR A SECOND TIME.FIVE PRIME THERAPEUTICS INC - MILESTONE FOR ANTIBODY TARGETING TIM-3 TRIGGERS $5 MILLION PAYMENT TO FIVE PRIME.FIVE PRIME- BMS EXTENDS RESEARCH COLLABORATION TERM FOR DEVELOPMENT, COMMERCIALIZATION FOR THERAPEUTICS IN 3 IMMUNE CHECKPOINT PATHWAYS TO MARCH 2019.FIVE PRIME THERAPEUTICS INC - BRISTOL-MYERS SQUIBB WILL ALSO PROVIDE ADDITIONAL FUNDING TO FIVE PRIME FOR EXTENDED TERM OF RESEARCH COLLABORATION.  Full Article

Bristol-Myers Estimates Tax Reform To Result In Additional Net Tax Expense Of About $3 Bln In Q4
Saturday, 6 Jan 2018 

Jan 5 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB - ESTIMATES THE IMPACT OF U.S. TAX REFORM TO RESULT IN ADDITIONAL NET TAX EXPENSE OF ABOUT $3 BILLION IN THE FOURTH QUARTER OF 2017‍​.BRISTOL-MYERS SQUIBB CO - CURRENTLY ESTIMATES THE NET IMPACT OF U.S. TAX REFORM ON THE NON-GAAP TAX RATE AS ROUGHLY NEUTRAL IN 2018‍​.BRISTOL-MYERS SAYS CHARGE TO IMPACT 2017 GAAP TAX RATE, EARNINGS PER SHARE GUIDANCE BUT NOT CO'S NON-GAAP GUIDANCE - SEC FILING.  Full Article

Aceto's Unit Launches Efavirenz Capsules, 50Mg, 200Mg
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Aceto Corp ::ACETO SUBSIDIARY, RISING PHARMACEUTICALS, LAUNCHES EFAVIRENZ CAPSULES, 50MG AND 200MG.SAYS UNIT ‍LAUNCHED GENERIC FOR EFAVIRENZ CAPSULES, AN FDA-APPROVED GENERIC VERSION OF REFERENCE LISTED DRUG SUSTIVA FROM BRISTOL MYERS SQUIBB​.  Full Article

Bristol-Myers Squibb Receives FDA Approval For Opdivo As Treatment For Patients With A Type Of Skin Cancer
Thursday, 21 Dec 2017 

Dec 20 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB RECEIVES FDA APPROVAL FOR OPDIVO (NIVOLUMAB) AS ADJUVANT THERAPY IN PATIENTS WITH COMPLETELY RESECTED MELANOMA WITH LYMPH NODE INVOLVEMENT OR METASTATIC DISEASE.  Full Article

Taris And Bristol-Myers Squibb Announce Clinical Trial Collaboration
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Bristol-Myers Squibb Co ::TARIS AND BRISTOL-MYERS SQUIBB ANNOUNCE CLINICAL TRIAL COLLABORATION.BRISTOL-MYERS SQUIBB - ‍IN CONJUNCTION WITH COLLABORATION, CO ALSO MADE AN EQUITY INVESTMENT IN TARIS​.BRISTOL-MYERS SQUIBB CO - ‍PHASE 1B STUDY TO COMBINE TAR-200 (GEMRIS) WITH OPDIVO (NIVOLUMAB) IN TREATMENT OF MUSCLE INVASIVE BLADDER CANCER​.  Full Article

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Yervoy (ipilimumab)
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF YERVOY (IPILIMUMAB) FOR THE TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH UNRESECTABLE OR METASTATIC MELANOMA.BRISTOL-MYERS SQUIBB CO - APPROVAL OF YERVOY FOR PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WHO HAVE UNRESECTABLE OR METASTATIC MELANOMA.  Full Article

Ono Pharmaceutical enters into license agreement with Bristol-Myers Squibb for Prostaglandin E2 receptor antagonists
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it entered into license agreement with Bristol-Myers Squibb Company (BMS)for Prostaglandin E2 receptor antagonists relating to Immuno-Oncology programs .Under the terms of this agreement, BMS is granted the rights to develop and commercialize ONO-4578 and other compounds from PGE2 receptor antagonist programs worldwide, except Japan, South Korea, Taiwan, China and Association of South-East Asian Nations (ASEAN)countries.In accordance with this agreement, ONO receives an upfront payment of $40 million from BMS.ONO will also receive subsequent clinical, regulatory and sales-based milestone payments, as well as royalties based on sales of the products in the countries where ONO granted BMS the rights for development and commercialization.  Full Article

Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting Immuno-Suppressive Factors In The Tumor Microenvironment
Thursday, 14 Dec 2017 

Dec 13 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB GRANTED EXCLUSIVE LICENSE BY ONO PHARMACEUTICAL FOR MULTIPLE PROGRAMS TARGETING IMMUNO-SUPPRESSIVE FACTORS IN THE TUMOR MICROENVIRONMENT.BRISTOL-MYERS SQUIBB CO - BRISTOL-MYERS SQUIBB WILL MAKE AN UPFRONT PAYMENT OF $40 MILLION TO ONO.BRISTOL-MYERS SQUIBB-WILL BE SOLELY RESPONSIBLE FOR DEVELOPMENT, MANUFACTURING,COMMERCIALIZATION OF ONO-4578,OTHER PGE(2) RECEPTOR ANTAGONIST PRODUCTS.  Full Article

U.S. FDA Accepts Bristol-Myers Squibb’S Application For Opdivo (Nivolumab) Plus Yervoy (Ipilimumab)
Thursday, 14 Dec 2017 

Dec 13 (Reuters) - Bristol-Myers Squibb Co ::U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) IN INTERMEDIATE- AND POOR-RISK PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AND GRANTS PRIORITY REVIEW.BRISTOL-MYERS SQUIBB CO - APPLICATION HAS AN ACTION DATE OF APRIL 16, 2018.BRISTOL-MYERS SQUIBB CO - APPLICATION BASED ON RESULTS FROM PHASE 3 CHECKMATE -214 STUDY.  Full Article

Bristol-Myers Squibb Announces 2.6 Pct Increase In Quarterly Dividend Beginning Q1 2018
Friday, 8 Dec 2017 

Dec 7 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ANNOUNCES DIVIDEND INCREASE.BRISTOL-MYERS SQUIBB CO - AN INCREASE OF 2.6% PERCENT IN COMPANY'S QUARTERLY DIVIDEND, BEGINNING IN Q1 OF 2018.BRISTOL-MYERS SQUIBB CO - DIVIDEND INCREASE WILL RESULT IN A QUARTERLY DIVIDEND OF 40 CENTS.  Full Article

Photo

Bristol-Myers to pay $1.85 billion in cancer deal with Nektar

Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.